Table 3. Spending by CMS Before and After Conversion to Standard Approval of Drugs Granted FDA Accelerated Approval, 2012 to 2017.

Drug	Approval year	Time on market, moa		CMS spending, $ in millionsb
				Medicare Part B		Medicare Part D		Medicaid
		Before	After	Before	After	Before	After	Before	After
Carfilzomib	2012	42	59	129.7	289.6	0.0	5.1	6.8	20.8
Everolimus	2012	41	59	0.0	0.0	0.7	5.4	4.3	44.2
Omacetaxine	2012	15	82	0.0	0.1	0.6	2.4	0.1	1.1
Ponatinib	2012	47	49	0.0	0.0	27.7	83.1	11.7	38.9
Ibrutinib	2013	8	77	0.0	0.0	246.0	1704.2	11.3	78.0
Pomalidomide	2013	26	68	0.0	0.0	263.2	920.2	12.0	47.6
Blinatumomab	2014	31	41	4.7	20.1	0.6	1.0	5.8	17.5
Ceritinib	2014	36	43	0.0	0.0	19.9	8.5	4.1	1.7
Nivolumab	2014	50	21	1227.9	1790.2	27.7	40.1	175.4	248.0
Olaparib	2014	31	40	0.0	0.0	44.9	228.0	7.3	48.1
Pembrolizumab	2014	15	60	0.0	1943.9	2.2	30.1	2.5	249.3
Alectinib	2015	22	37	0.0	0.0	37.5	87.8	8.2	29.3
Daratumumab	2015	12	49	0.0	696.7	5.0	14.1	3.6	41.2
Deferasiroxc	2015	37	31	0.0	0.0	132.5	149.6	148.7	133.1
Idarucizumab	2015	29	32	0.0	0.0	0.0	0.0	0.0	0.0
Osimertinib	2015	16	45	0.0	0.0	135.5	546.1	19.3	71.7
Palbociclib	2015	25	45	0.0	0.0	827.4	1838.8	129.3	317.4
Rucaparib	2016	15	32	0.0	0.0	21.3	59.1	5.0	8.7
Venetoclax	2016	25	30	0.0	0.0	58.8	409.8	3.4	18.8
Avelumab	2017	39	6	29.4	51.6	0.4	0.9	0.8	2.9
Brigatinib	2017	36	7	0.0	0.0	12.1	18.1	2.9	4.7
Deferasiroxc	2017	11	31	0.0	0.0	1.5	4.0	4.7	14.0
Median (IQR)		28 (15-37)	42 (31-57)	0.0 (0.0-0.0)	0.0 (0.0-15.1)	20.6 (0.9-55.3)	35.1 (5.2-208.4)	5.4 (3.4-11.6)	34.1 (10.1-65.8)

Abbreviations: CMS, Centers for Medicare & Medicaid Services; FDA, US Food and Drug Administration.

^a Through December 31, 2020.

^b Prorated based on the month of conversion to standard approval.

^c Two formulations of deferasirox were separately granted accelerated approval, shared confirmatory trials, and were converted on the same date; CMS spending data for these formulations were reported separately.